Mariner LLC Has $3.30 Million Stake in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Mariner LLC lifted its position in Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Free Report) by 33.9% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 26,803 shares of the specialty pharmaceutical company's stock after buying an additional 6,782 shares during the period. Mariner LLC's holdings in Jazz Pharmaceuticals were worth $3,301,000 at the end of the most recent reporting period.

Other institutional investors have also modified their holdings of the company. Pacer Advisors Inc. raised its stake in Jazz Pharmaceuticals by 5.5% during the 4th quarter. Pacer Advisors Inc. now owns 2,214,480 shares of the specialty pharmaceutical company's stock valued at $272,713,000 after purchasing an additional 115,102 shares during the period. GW&K Investment Management LLC raised its position in Jazz Pharmaceuticals by 26.6% during the fourth quarter. GW&K Investment Management LLC now owns 464,003 shares of the specialty pharmaceutical company's stock valued at $57,142,000 after buying an additional 97,589 shares during the period. Connor Clark & Lunn Investment Management Ltd. lifted its stake in Jazz Pharmaceuticals by 501.4% in the 4th quarter. Connor Clark & Lunn Investment Management Ltd. now owns 112,055 shares of the specialty pharmaceutical company's stock worth $13,800,000 after acquiring an additional 93,422 shares in the last quarter. Raymond James Financial Inc. purchased a new stake in shares of Jazz Pharmaceuticals in the fourth quarter worth approximately $11,373,000. Finally, Charles Schwab Investment Management Inc. boosted its holdings in shares of Jazz Pharmaceuticals by 15.8% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 615,517 shares of the specialty pharmaceutical company's stock worth $75,801,000 after purchasing an additional 83,807 shares during the period. Institutional investors and hedge funds own 89.14% of the company's stock.

Jazz Pharmaceuticals Trading Up 1.7 %

NASDAQ JAZZ traded up $1.82 during trading hours on Friday, hitting $110.80. The company's stock had a trading volume of 896,340 shares, compared to its average volume of 797,223. Jazz Pharmaceuticals plc has a twelve month low of $95.49 and a twelve month high of $148.06. The firm has a market capitalization of $6.73 billion, a P/E ratio of 15.61, a PEG ratio of 1.04 and a beta of 0.42. The company has a quick ratio of 3.74, a current ratio of 4.26 and a debt-to-equity ratio of 1.46. The stock has a fifty day moving average of $124.64 and a 200 day moving average of $122.21.

Insider Buying and Selling at Jazz Pharmaceuticals

In related news, EVP Neena M. Patil sold 3,800 shares of Jazz Pharmaceuticals stock in a transaction that occurred on Thursday, February 27th. The shares were sold at an average price of $144.87, for a total transaction of $550,506.00. Following the transaction, the executive vice president now owns 33,318 shares of the company's stock, valued at $4,826,778.66. This trade represents a 10.24 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CAO Patricia Carr sold 4,813 shares of the business's stock in a transaction on Thursday, February 27th. The shares were sold at an average price of $144.42, for a total transaction of $695,093.46. Following the completion of the transaction, the chief accounting officer now directly owns 8,237 shares of the company's stock, valued at $1,189,587.54. This trade represents a 36.88 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 28,736 shares of company stock valued at $4,023,305. 4.20% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on the stock. Morgan Stanley reiterated an "overweight" rating and issued a $183.00 target price (up previously from $175.00) on shares of Jazz Pharmaceuticals in a research report on Friday, March 7th. JPMorgan Chase & Co. lifted their price objective on Jazz Pharmaceuticals from $200.00 to $209.00 and gave the company an "overweight" rating in a research report on Wednesday, February 26th. Royal Bank of Canada dropped their target price on Jazz Pharmaceuticals from $179.00 to $178.00 and set an "outperform" rating on the stock in a research report on Wednesday, February 26th. Wells Fargo & Company raised Jazz Pharmaceuticals from an "equal weight" rating to an "overweight" rating and raised their price target for the stock from $130.00 to $170.00 in a research note on Thursday, February 13th. Finally, HC Wainwright increased their price objective on Jazz Pharmaceuticals from $200.00 to $217.00 and gave the stock a "buy" rating in a report on Monday, March 10th. One analyst has rated the stock with a hold rating, thirteen have given a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat, the company presently has a consensus rating of "Buy" and an average target price of $187.71.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.